Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
Status:
Completed
Trial end date:
2018-06-05
Target enrollment:
Participant gender:
Summary
To investigate the pharmacodynamics and safety of FYU-981 administered orally once a day for
14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male
hyperuricemic outpatients with or without gout.